Emerging C-MET Metastatic NSCLC therapies—such as TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab, and Capmatinib Combination Therapy—are expected to drive growth in the C-MET Metastatic NSCLC market in the coming years.
DelveInsight has published a new report titled "C-MET Metastatic NSCLC - Market Insights, Epidemiology, and Market Forecast-2034,” providing a comprehensive analysis of C-MET Metastatic NSCLC, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the C-MET Metastatic NSCLC market report @ https://www.delveinsight.com/report-store/cmet-mnsclc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the C-MET Metastatic NSCLC Market Report:
-
The overall c-MET metastatic NSCLC market across the seven major markets (7MM) was estimated at approximately USD 590 million in 2023 and is expected to expand with the introduction of new therapies. The U.S. led the market, contributing around 75% of the total value.
-
In May 2025, the FDA granted accelerated approval to telisotuzumab vedotin (Emrelis, AbbVie) for adults with locally advanced or metastatic non-squamous NSCLC exhibiting high c-Met protein overexpression (≥50% of tumor cells with strong staining) who had received prior systemic therapy. This approval was supported by Phase II LUMINOSITY trial data, which showed a 35% overall response rate in patients with high c-Met expression. The FDA also approved the VENTANA MET (SP44) RxDx assay as a companion diagnostic to identify eligible patients for Emrelis therapy.
-
In 2023, around 524,000 new NSCLC cases were reported across the 7MM, with numbers projected to rise over the forecast period. In the U.S. alone, approximately 202,500 new cases were reported that year.
-
TABRECTA (capmatinib) and TEPMETKO (tepotinib) are FDA-approved small-molecule inhibitors targeting MET exon 14 skipping mutations, providing critical treatment options for NSCLC patients with MET alterations. TABRECTA is expected to maintain a leading position due to its early market entry. In May 2024, early results from the METalmark trial indicated that the combination of amivantamab and TABRECTA showed promising safety and efficacy in advanced MET-driven NSCLC, with a Phase II recommended dose established.
-
In 2023, off-label use of crizotinib and other targeted therapies accounted for approximately USD 100 million of the U.S. c-MET NSCLC market, while TABRECTA generated around USD 200 million. However, TABRECTA was withdrawn from the German market due to challenges with the AMNOG health technology assessment, as the G-BA concluded in February that no proven additional benefit existed for certain advanced NSCLC patients. Remaining supplies are expected to last until March 2024, after which access will be limited to named patient programs requiring insurer approval.
-
Despite progress with MET TKIs, antibody therapies, and antibody-drug conjugates, opportunities remain to enhance treatment efficacy in NSCLC with MET alterations.
-
Key C-MET Metastatic NSCLC companies, including Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, and others, are actively developing new therapies to advance the treatment landscape.
-
Promising pipeline therapies include TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab, Capmatinib Combination Therapy, and others.
C-MET Metastatic NSCLC Overview
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for roughly 85% of all cases. It is mainly categorized into adenocarcinomas, squamous cell carcinomas, and large cell carcinomas, with less common subtypes including adenosquamous and sarcomatoid carcinomas.
The MET gene, located on chromosome 7q31.2, encodes the c-Met receptor, a transmembrane tyrosine kinase. In normal epithelial cells, c-Met is expressed at low levels, but in various cancers—including NSCLC, renal cell carcinoma, colorectal cancer, and liver cancer—its expression can increase dramatically, sometimes by 2- to 50-fold.
C-MET inhibitors have demonstrated anticancer effects against NSCLC in preclinical and clinical studies. However, due to the genetic complexity of NSCLC, these treatments are likely to benefit only a specific subset of patients.
C-MET Metastatic NSCLC Market Outlook
Historically, research on MET as a cancer-driving factor in NSCLC concentrated primarily on MET gene amplification, which occurs in only a small fraction of patients. Early studies indicated that targeting MET amplification with specific drugs could provide clinical benefit. More recent research, however, has shown that a larger subset of NSCLC patients carry MET mutations, especially those causing MET exon 14 skipping. These mutations prevent normal degradation of the MET protein, leading to its accumulation and promoting tumor growth. MET exon 14 skipping is now recognized as a key driver in approximately 3–4% of NSCLC cases.
Currently, two MET tyrosine kinase inhibitors (TKIs), TABRECTA and TEPMETKO, are approved globally for treating NSCLC with MET exon 14 alterations. In China, savolitinib is the only approved MET-targeted therapy. Other potential options include participation in clinical trials for new MET-targeting agents, immunotherapy with or without chemotherapy, or off-label use of crizotinib.
For NSCLC patients without known driver mutations, first-line therapy generally consists of platinum-based chemotherapy or immune checkpoint inhibitors (ICIs), alone or in combination, based on PD-L1 expression and overall patient condition. In the second-line setting, ICIs may be used as monotherapy if not given previously. For patients with actionable oncogenic drivers, targeted therapies are preferred, as standard chemotherapy or ICIs are typically less effective in tumors driven by specific genetic alterations.
Discover how the C-MET Metastatic NSCLC market is rising in the coming years @ https://www.delveinsight.com/sample-request/cmet-mnsclc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
C-MET Metastatic NSCLC Marketed Drugs
-
TABRECTA (capmatinib): Novartis
-
TEPMETKO (tepotinib): EMD Serono/Merck KGaA
C-MET Metastatic NSCLC Emerging Drugs
-
Telisotuzumab Vedotin: AbbVie
-
REGN5093 and REGN5093-M114: Regeneron Pharmaceuticals
Scope of the C-MET Metastatic NSCLC Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key C-MET Metastatic NSCLC Companies: Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, and others
-
C-MET Metastatic NSCLC Therapeutic Assessment: C-MET Metastatic NSCLC current marketed and C-MET Metastatic NSCLC emerging therapies
-
C-MET Metastatic NSCLC Market Dynamics: C-MET Metastatic NSCLC market drivers and C-MET Metastatic NSCLC market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
C-MET Metastatic NSCLC Unmet Needs, KOL's views, Analyst's views, C-MET Metastatic NSCLC Market Access and Reimbursement
To know what’s more in our C-MET Metastatic NSCLC report, visit https://www.delveinsight.com/report-store/cmet-mnsclc-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the C-MET Metastatic NSCLC Market Report:
-
C-MET Metastatic NSCLC market report covers a descriptive overview and comprehensive insight of the C-MET Metastatic NSCLC Epidemiology and C-MET Metastatic NSCLC market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The C-MET Metastatic NSCLC market report provides insights into the current and emerging therapies.
-
The C-MET Metastatic NSCLC market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The C-MET Metastatic NSCLC market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the C-MET Metastatic NSCLC market.
Got queries? Click here to know more about the C-MET Metastatic NSCLC market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. C-MET Metastatic NSCLC Patient Share (%) Overview at a Glance
5. C-MET Metastatic NSCLC Market Overview at a Glance
6. C-MET Metastatic NSCLC Disease Background and Overview
7. C-MET Metastatic NSCLC Epidemiology and Patient Population
8. Country-Specific Patient Population of C-MET Metastatic NSCLC
9. C-MET Metastatic NSCLC Current Treatment and Medical Practices
10. Unmet Needs
11. C-MET Metastatic NSCLC Emerging Therapies
12. C-MET Metastatic NSCLC Market Outlook
13. Country-Wise C-MET Metastatic NSCLC Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. C-MET Metastatic NSCLC Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about C-MET Metastatic NSCLC Market Outlook 2034
Related Reports:
C-MET Metastatic NSCLC Pipeline Insights, DelveInsight
"C-MET Metastatic NSCLC Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the C-MET Metastatic NSCLC market. A detailed picture of the C-MET Metastatic NSCLC pipeline landscape is provided, which includes the disease overview and C-MET Metastatic NSCLC treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
